

# Paul Eliezer Oberstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/439623/publications.pdf>

Version: 2024-02-01

33  
papers

3,409  
citations

471061

17  
h-index

454577

30  
g-index

37  
all docs

37  
docs citations

37  
times ranked

6075  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2014, 25, 735-747.	7.7	1,616
2	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 359-366.	0.8	350
3	Pancreatic cancer: why is it so hard to treat?. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 321-337.	1.4	250
4	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	0.8	233
5	Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. <i>Cancer Discovery</i> , 2018, 8, 1458-1473.	7.7	158
6	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE) <i>Tj ETQq0 0 0 rgBT/Overloc170 Tf 50</i>	1.2	37
7	Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. <i>Gut</i> , 2019, 68, 1034-1043.	6.1	147
8	Current and Emerging Therapies in Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1670-1678.	3.2	114
9	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44073-44081.	0.8	63
10	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
11	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	3.2	37
12	Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) <i>&lt;i&gt;in vivo&lt;/i&gt;</i> . <i>Theranostics</i> , 2020, 10, 4614-4626.	4.6	33
13	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE) <i>Tj ETQq1 1 0.7846.14 rgBT/39 Overloc</i>	1.2	37
14	Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. <i>Clinical Cancer Research</i> , 2020, 26, 1297-1308.	3.2	30
15	Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	24
16	Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7319.	0.6	18
17	Uptake and Patterns of Use of Gemcitabine for Metastatic Pancreatic Cancer: A Population-Based Study. <i>Cancer Investigation</i> , 2013, 31, 316-322.	0.6	18
18	Reply to "H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines"™. <i>Nature Genetics</i> , 2019, 51, 1427-1428.	9.4	15

#	ARTICLE	IF	CITATIONS
19	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice, 2021, 17, 607-614.	1.4	7
20	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2017, 35, 380-380.	0.8	6
21	Metastatic Gastric Large Cell Neuroendocrine Carcinoma: A Case Report and Review of Literature. Clinical Colorectal Cancer, 2012, 11, 218-223.	1.0	5
22	The Achillesâ€™ Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. Journal of Pancreatology, 2020, 3, 121-131.	0.3	5
23	Pancreatic neuroendocrine tumors: entering a new era. JOP: Journal of the Pancreas, 2012, 13, 169-73.	1.5	5
24	Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2012, 13, 368-71.	1.5	5
25	Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP: Journal of the Pancreas, 2011, 12, 358-61.	1.5	4
26	Update on novel therapies for pancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2012, 13, 372-5.	1.5	3
27	The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.. Journal of Clinical Oncology, 2013, 31, 308-308.	0.8	2
28	Prospective phase II trial of GTX in metastatic pancreatic cancer: Laboratory and clinical studies.. Journal of Clinical Oncology, 2013, 31, 209-209.	0.8	1
29	A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, TPS197-TPS197.	0.8	1
30	Abstract 1637: Depletion of tumor stroma with Smoothed inhibition leads to altered epithelial differentiation and paradoxical acceleration of pancreatic tumorigenesis.. , 2013, , .		0
31	Uptake and patterns of use of gemcitabine for stage IV pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, e15074-e15074.	0.8	0
32	Gastric cancer prevention and early detection program for an at-risk population: A prospective study of the Korean American community.. Journal of Clinical Oncology, 2015, 33, 42-42.	0.8	0
33	Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.. Journal of Clinical Oncology, 2018, 36, TPS534-TPS534.	0.8	0